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outside of the current COVID-19 pandemic. Home
UTI PCR testing revealed common uropathogens
for a population with a high proportion of recurrent
UTI, but additional research comparing home
versus in-office urine PCR testing is necessary.
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Introduction: Urinary Tract Infections (UTIs) pose
a significant health concern for patients. The gold
standard for diagnosis is a urine culture with
speciation and sensitivities. Polymerase chain
reaction (PCR) testing is a newer, alternative
option for uropathogen detection and is now being
evaluated to diagnose UTIs. During the COVID-19
pandemic, we sought to evaluate patient
satisfaction with a novel multiplex PCR UTI home
collection kit for symptomatic UTI in a
urogynecologic population.
Methods: This was a cross-sectional study of
women in an academic urogynecology practice
undergoing evaluation for symptomatic UTI from
April 1 through July 15, 2020. Patients were sent a
UTI PCR home kit when they called for UTI
symptoms. We created a survey on a 5-point
Likert scale to assess patient satisfaction with the
process. We called patients with this survey along
with a few additional questions. Baseline
information including demographics, symptoms
and results of testing were collected. The primary
outcome was patient satisfaction with this
experience. Secondary outcomes included type
and number of uropathogens on testing.
Results: A total of 30 patients [73% white race,
mean age 71.9 (SD 12.0), mean BMI 31.9 (SD
8.0)] with UTI symptoms underwent testing.
Patients responded with a mean score of 4.7 to all
questions. (Table 1) Overall, 86% (26/30) of
patients reported that they would choose this test
again if given the opportunity, and 86% of those
asked would choose this test again outside of the
COVID-19 pandemic. The most common
symptoms reported included dysuria (53%),
urgency (37%), and frequency (30%). The most
common pathogens identified included E. coli
(70%), E. faecalis (60%) and A. urinae (43%),
among others. There were 21 patients (70%) that
developed UTI symptoms again after treatment
and the average time to reach out to the health
care system after their initial PCR test was 24.5
days (SD 28.0).
Conclusion: Patients were satisfied with their
experience utilizing a home multiplex UTI PCR kit
and patients would choose this option again, even
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Introduction: The two main challenges during the
COVID 19 pandemic were to keep essential
employees safe and to provide timely care to
patients. We devised a novel urine specimen
home pickup strategy for our patients with
hematuria, irritative voiding symptoms as well as
bladder cancer to address these issues.
Methods: An employee dropped off necessary
equipment for the urine sample to symptomatic
patients’ houses. A clean catch specimen was
collected and the sample left at the front door. The
driver wearing PPE picked up the sample within
30 minutes and delivered it to the lab. Dipstick
analysis was performed. Patients with leukocyte

esterase or nitrate positive urine had a PCR
culture. For patients who had hematuria with no
previous cytology, a urine cytology and a PCR
urine culture was ordered. Patients with a history
of bladder cancer had cytology and FISH done.
Urinalysis results were immediately sent to the
physician via electronic medical records and a
follow-up telemedicine appointment was
scheduled. A retrospective analysis was
performed for 2206 samples collected: 1122
(79.5% positive) from the office as controls and
1084 (82.7% positive) collected at home. Average
turnaround time (TAT) was 1.96 days with average
transit time of 0.70 days. TATs were faster for
samples collected at home for both parameters.
Results: 1148 patients were diagnosed with a
clinically significant bacterial (>105 colonies) or
yeast infection, (53.5% of office samples and
50.6% of home samples). A significant number of
infections were caused by bacteria including
Pseudomonas, Klebsiella, Proteus and E. Coli.
Klebsiella pneumoniae, Streptococcus agalactiae,
and Aerococcus urinae were significantly more
common in home speciments than office

specimens. Yeast infections with Candida
Glabarata was found more often in home samples
(p = 0.0153). Viral microbes were detected at the
same rate, regardless of collection location. Nine
of 74 (12%) FISH tests and 26 of 611 (4%)
cytologies were abnormal leading to additional
work up.
Conclusion: Symptomatic urology patients were
able to receive impactful healthcare while
remaining sheltered in place during Covid 19 via
our novel mobile care approach.
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Introduction: Urinary tract infections affect up to
50% of women each year. Some have recurrent
urinary tract infections (RUTIs; >3 UTI/year) and
require repeated and/or prophylactic antibiotic
courses1 which can lead to development of
antibiotic resistance without UTI resolution. Prior
cystoscopic studies have noted areas of chronic
inflammation (trigonitis when limited to trigone)
that can house bacterial persistence2.
Electrofulguration (EF) is an outpatient endoscopic
cauterizing technique which eliminates these
areas of inflammation to eradicate these deeply
seated bacteria3. The goal of this study is to
evaluate the response to EF for trigonitis alone in
women with antibiotic-recalcitrant RUTIs.
Methods: Following IRB approval, a retrospective
chart review of women who underwent EF of
limited trigonitis to treat their antibiotic-recalcitrant
RUTIs and had a minimum 1 year follow-up was
undertaken. RUTIs were classified as antibioticrecalcitrant secondary to high rates of antibioticresistance, antibiotic allergies or no durable
response to long-term antibiotic suppression.
Primary outcome was number of symptomatic UTI
episodes requiring antibiotics post-EF, leading to
definitions of cure (0/year), improvement (1-2
UTI/year) and failure (>3 UTI/year). Secondary
outcome was endoscopic success based on
complete resolution of trigonitis during an office
cystoscopy at 6 months after EF.
Results: From 2008-2018, 74 non-neurogenic
women met study criteria (Group 1: 64 (86%)
endoscopic success, Group 2: 10 (14%)
endoscopic failure). There was no statistically
significant difference in patient characteristics or
pre-operative UTI management. Median follow-up
in group 1 was 3.5 years (IQR 1.7-6.2) and 2.6
years (IQR 1.8-7.5) in group 2 (p=0.75). Median
UTIs/year post-EF were 0.6 in both groups.
Clinical outcomes between groups were not
statistically different, with overall 16 (22%) cured,
54 (73%) improved and 4 (5%) failed. In the
clinically improved group, 38 (70%) had <1
UTI/year in the follow-up period starting 6 months
after EF. No patients remained on long term,

